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Abstract 
The objective of this study was to assess the association of sex and the apolipoprotein E (APOE) ε4 allele with 
brain tau deposition and atrophy in older adults with Alzheimer’s disease (AD) using quantitative 18F-AV-1451 
positron emission tomography (PET) and magnetic resonance imaging (MRI). 
Methods: Preprocessed 18F-AV-1451 tau PET, raw T1-weighted structural MR images, demographic 
information, cerebrospinal fluid (CSF) total tau (t-tau) and phosphorylated tau (p-tau) measurements from 57 
elderly individuals with AD were downloaded from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) 
database. An iteratively reblurred Van Cittert partial volume correction (PVC) method was applied to all 
preprocessed PET images. MRI images were used for PET spatial normalization and gray matter volume 
calculation. 18F-AV-1451 PET standardized uptake value ratio (SUVR) was calculated relative to the cerebellum 
gray matter. The effect of sex and APOE ε4 status on SUVR and gray matter volume were assessed at both 
region of interest (ROI) and voxelwise levels. 
Results: Female APOE ε4 carriers (FACs) had significant higher 18F-AV-1451 SUVRs in the lateral temporal, 
parietal, posterior cingulate, medial temporal, inferior temporal, entorhinal cortex, amygdala and 
parahippocampal gyrus regions, and exhibited smaller gray matter volumes in the posterior cingulate, medial 
temporal, inferior temporal and amygdala regions, as compared to the non-FACs (NFACs) comprised of female 
APOE ε4 non-carriers, male APOE ε4 carriers and male APOE ε4 non-carriers. Voxelwise analysis revealed 
forebrain and limbic clusters with greater 18F-AV-1451 SUVRs and lower gray matter volume between FACs 
compared to the NFACs. Negative correlations between ROI 18F-AV-1451 SUVRs and gray matter volumes 
were significant after adjusting for age and years of education. 
Conclusions: Among elderly individuals with AD, sex modified the effects of the APOE ε4 allele on 
region-specific tau deposition and gray matter volume. FACs had elevated brain region-specific tau PET SUVR 
and decreased gray matter volume in comparison to NFACs. The study provides a basis for the use of precision 
medicine in the diagnosis of AD and evaluation of therapeutics using 18F-AV-1451 PET and structural MRI. 
Key words: Alzheimer’s disease, Tau PET, Sex, APOE, Neurodegeneration 
Introduction 
The apolipoprotein E (APOE) ε4 gene has 
emerged as a major genetic risk factor for Alzheimer’s 
disease (AD) [1-3]. APOE ε4 is associated with AD- 
related biological markers including cerebrospinal 
fluid (CSF) total tau (t-tau), phosphorylated tau 
(p-tau), brain tau deposition, and gray matter atrophy 
[4-9]. 
In addition to APOE ε4, sex also plays an 
important role in AD risk, with females having a 
higher lifetime risk of developing AD than males [10, 









degeneration have been identified in healthy older 
adults and patients with AD [12-14]. The Lancet 
Neurology Commission has recently asserted that 
greater attention to sex differences in AD is essential 
to advancing both disease prevention and treatment 
strategies in AD [15]. 
Numerous CSF and epidemiological evidence 
support modulatory effects of APOE ε4 on sex-specific 
disease risk and neuropathology in AD. For example, 
female APOE ε4 carriers (FACs) have a greater risk of 
developing AD [16, 17] and far more pronounced 
disease progression [18]. Studies of CSF t-tau and 
p-tau have suggested that FACs accumulate more tau 
pathology than males in clinically normal older adults 
[19], patients with mild cognitive impairment (MCI) 
[18], and even mixed diagnostic cohorts (clinically 
normal older adults, MCI and AD) [13]. In addition, 
emerging evidence suggests that the cortical tau 
measured by quantitative positron emission 
tomography (PET) is temporally and prospectively 
related to the degree of neurodegeneration and 
current cognitive status [20-23]. Two recent studies 
have investigated how sex modulates the effect of 
APOE ε4 on brain tau deposition using quantitative 
18F-AV-1451 PET. One study focused on clinically 
normal individuals in a 2-cohort study, and showed a 
significant sex by APOE ε4 interaction effect on 
regional tau retention [12]. Our previous work 
reported a significant APOE ε4 by sex interaction 
effect on regional brain tau deposition in individuals 
with MCI [24]. These two studies suggest that FACs 
exhibit brain regions with increased tau deposition 
among cognitively normal older adults and 
individuals with MCI. 
Cross-sectional structural magnetic resonance 
imaging (MRI) studies have shown a similar APOE ε4 
interaction effect on gray matter atrophy. In MCI, the 
effect of APOE ε4 on hippocampal volume reduction 
was stronger in females versus males [25]. Similarly 
among AD patients, FACs had significantly smaller 
hippocampal volume compared to female APOE ε4 
non-carriers, which, however, was not observed in 
males [9]. 
Understanding these APOE ε4 by sex interaction 
effects may help us identify and apply customized 
prevention strategies for different populations against 
AD. The evidence of how sex in association with 
APOE ε4 affects tau PET and gray matter volume, and 
whether tau pathology is associated with neuro-
degeneration in patients with AD remain poorly 
understood. The objective of the present study was to 
assess whether sex modulates the effects of the APOE 
ε4 allele on brain tau deposition and atrophy in older 
adults with AD. 
Methods 
Participants 
We included 57 participants from the 
Alzheimer’s Disease Neuroimaging Initiative (ADNI) 
who had (i) a clinical diagnosis of AD, (ii) undergone 
18F-AV-1451 tau PET, (iii) high resolution 3D 
T1-weighted structural MRI, and (iv) APOE ε4 
genotyping information. Consent was obtained from 
all participants prior to the start of the study. For each 
subject, the most recent tau PET and T1-weighted MRI 
scan were included. A full list of study inclusion and 
exclusion criteria can be found at https://adni.loni. 
usc.edu/wp-content/uploads/2008/07/adni2-proce
dures-manual.pdf. 
PET and MRI data acquisition and processing 
Preprocessed 18F-AV-1451 PET images and raw 
T1-weighted images were downloaded from the 
ADNI database (http://adni.loni.usc.edu/). The 
18F-AV-1451 PET acquisition parameters can be found 
at http://adni.loni.usc.edu/methods/pet-analysis- 
method/pet-analysis/. The PET images had been 
previously aligned, averaged, reoriented and inter-
polated into a standard image space with uniform 
voxel size (image volume 160 × 160 × 96, 1.5 × 1.5 × 1.5 
mm3 in x, y, z), and then were smoothed to a uniform 
resolution of 8 mm in full width at half maximum 
(FWHM) by the ADNI consortium. 
As described in our previous studies [24, 26], we 
further processed the downloaded PET images for 
partial volume correction (PVC) and spatial 
normalization using Statistical Parametric Mapping 
(SPM12, Wellcome Department of Imaging 
Neuroscience, Institute of Neurology, London, UK) 
with CAT12 toolbox (CAT12: http://www.neuro.uni- 
jena.de/cat/) and MATLAB R2019b (The MathWorks 
Inc). PVC was applied to the processed PET images to 
correct for or minimize potential underestimation in 
PET quantification. In brief, an iterative reblurred Van 
Cittert method [27] was used for PVC on the PET 
images. The algorithm was implemented using a 3-D 
Gaussian kernel with 8 mm FWHM, step length α 
=1.5, and an iteration stop criterion of relative percent 
change of PVC images < 1%. All PET images with 
PVC were then coregistered to the corresponding 
structural MRI images. The MRI images were 
normalized to standard Montreal Neurologic Institute 
(MNI) space using SPM12 with a MRI template 
(image volume: 121×145×121, voxel size: 1.5×1.5×1.5 
mm3 in x, y, z). The transformation parameters 
determined by MRI spatial normalization were then 
applied to the coregistered PET images for PET spatial 
normalization. Regions of interest (ROIs) including 
cerebellum gray matter as a reference tissue were 





manually drawn on the MRI template using PMOD 
(version 4.002; PMOD Technologies Ltd., Zürich, 
Switzerland) in standard MNI space. SUVR images 
were calculated relative to the cerebellum gray matter. 
SUVR images without PVC were also generated for 
reference. 
Braak Stage related 12 ROIs, including the 
entorhinal cortex, parahippocampal, amygdala, 
inferior temporal, medial temporal, lateral temporal, 
posterior cingulate, posterior precuneus, parietal, 
occipital, orbital frontal, and prefrontal, were also 
defined in the MNI space [22, 24, 26]. The SUVR of 
each ROI was obtained by calculating the mean of the 
values within each ROI on the PVC and without PVC 
PET images in the MNI space. The choice to compute 
ROI SUVRs in standard space was made to minimize 
variance related to the variability of ROI volume and 
shape in native space [24, 26, 28, 29]. 
Gray matter volume was calculated using the 
CAT12 toolbox extension of SPM12. CAT12 
preprocessing was conducted following the standard 
default procedure suggested in the manual. First, 
structural T1-weighted MRI images were segmented 
into gray matter, white matter and CSF. Then, gray 
matter segmentations were warped to MNI space 
with modulated spatial normalization. Finally, the 12 
cortical ROIs gray matter volumes were calculated 
from the modulated gray matter images. 
APOE genotyping, CSF t-tau and p-tau 
assessment 
A 10 ml sample of peripheral blood was 
collected from each subject for direct APOE 
genotyping. Restriction enzyme isoform genotyping 
was performed on the extracted DNA to test for the 
presence of the APOE ε4 genotype, as described 
previously [30]. APOE ε4 carriers were defined as 
participants who had one or more ε4 allele (ε4/ ε4, ε4/ 
ε3 and ε4/ ε2). Those without any ε4 allele were 
defined as APOE ε4 non-carriers. CSF samples were 
acquired through lumbar puncture as described in 
ADNI: http://adni.loni.usc.edu/methods/ 
documents/. The Roche study protocol developed by 
the UPenn/ADNI Biomarker Laboratory was used for 
Aβ42, t-tau, and p-tau CSF quantification, as 
described in previously [31, 32]. 
Statistical analysis 
Recent studies have found no significant 
differences among non-FACs (NFACs, including 
female APOE ε4 non-carriers, male APOE ε4 carriers 
and male APOE ε4 non-carriers) in 18F-AV-1451 ROI 
SUVRs in cognitively normal adults [12] and 
individuals with MCI [24]. In the current tau PET 
study, we first tested the hypothesis that previous 
results from cognitively normal and MCI cohorts hold 
true in our AD cohort. Statistical analysis using 
generalized linear models (GLMs) proc with 
LS-means/pdiff, implemented in Statistical Analysis 
System (SAS version 9.4, SAS Institute, Inc.), 
confirmed that 18F-AV-1451 SUVR did not 
significantly differ among NFACs in any of the 12 
study ROIs. Specifically, no regions were significantly 
different in an overall test of significance between 
NFAC groups with P values ranging from 0.19 for the 
medial temporal to 0.99 for the occipital. Likewise, in 
pairwise intergroup comparisons (i.e. female APOE ε4 
non-carriers vs. male APOE ε4 carriers, female APOE 
ε4 non-carriers vs. male APOE ε4 non-carriers, and 
male APOE ε4 carriers vs. male APOE ε4 
non-carriers), no regions were significantly different 
with P values ranging from 0.09 for the inferior 
temporal female APOE ε4 non-carriers vs. male APOE 
ε4 non-carriers in comparison to 0.99 for the posterior 
precuneus female APOE ε4 non-carriers vs. male 
APOE ε4 carriers comparison. Based on this finding, 
in order to increase statistical power, all subsequent 
analyses compared FACs to the NFACs. SAS9.4 and 
SPM12 were used for all statistical analyses. GLMs 
adjusted for age and years of education were used to 
assess group differences in SUVR and gray matter 
volume for both ROI and voxelwise analyses. For ROI 
analyses, P < 0.05 was considered significant. For 
voxelwise analyses, an uncorrected P < 0.001 and 
cluster size > 100 voxels were defined as significant. 
Additional statistical results with multiple 
comparison corrections are discussed in the 
Discussion section. To investigate whether regional 
tau retention was associated with neurodegeneration, 
the correlation between ROIs 18F-AV-1451 SUVRs and 




A total of 57 AD subjects (mean age: 78.98 ± 9.22 
years, 25 females (44%), 34 APOE ε4 carriers (60%)) 
with 18F-AV-1451 PET and structural MRI scans were 
included in the study. Demographic characteristics, 
cognitive function and CSF Aβ42, t-tau and p-tau 
levels of FACs and NFACs are listed in Table 1. There 
were no significant differences in age and years of 
education between males and females for either the 
APOE ε4 carrier group or the non-carrier group (P > 
0.05). Performance on the Mini-Mental State 
Examination (MMSE), global Clinical Dementia 
Rating (CDR) and CDR-sum of boxes (CDR-SOB) 
score (P > 0.05) were not significantly different among 
the four subgroups, after adjusting for age and years 





of education. Chi-squared analysis revealed no 
significant difference in the proportion of individuals 
with APOE ε4 ε4/ ε4 ε3/ ε4 ε2 genotypes (P = 0.95) 
between males and females. 
 
Table 1. Study cohort characteristics 
Parameter Female APOE 
ε4+ (n = 15) 
Female APOE 
ε4- (n = 10) 
Male APOE 
ε4+ (n = 19) 
Male APOE 
ε4- (n = 13) 
Age (years) 76.58±7.98 79.26±11.60 79.32±8.63 81.06±9.86 
Education (years) 14.73±1.94 13.50±2.01 17.11±2.62 16.00±2.71 
MMSE  21.20±4.59 20.10±5.86 22.79±4.40 22.15±5.16 
Global CDR  1.13±0.48 1.20±0.59 0.87±0.50 0.88±0.42 
CDR-SOB 1.38±1.90 3.56±4.27 1.46±2.79 1.00±1.84 
APOE 
ε4ε4/ε4ε3/ε4ε2 
5/8/2 - 6/11/2 - 
CSF Aβ42 (pg/mL) 589.56±180.47 795.35±262.64 625.24±195.16 722.17±343.62 
CSF t-tau (pg/mL) 433.03±202.33 343.43±191.15 341.76±109.82 333.44±180.90 
CSF p-tau (pg/mL) 43.31±25.37 31.60±21.84 34.19±11.86 33.34±21.58 
Notes. CDR: Clinical Dementia Rating; CDR-SOB: Clinical Dementia Rating Scale 
sum of boxes; CSF: cerebrospinal fluid; MMSE: Mini-Mental State Examination. 
 
Sex modifies the APOE ε4 effect on brain tau 
deposition measured by 18F-AV-1451 PET 
SUVR 
Mean 18F-AV-1451 SUVR images in Figure 1 
visually demonstrate that FACs have higher SUVR in 
both PVC and without PVC images in comparison the 
NFACs. Compared to the without PVC images 
(Figure 1B), the mean 18F-AV-1451 SUVR images with 
PVC in Figure 1A exhibit a higher SUVR contrast 
between APOE ε4 carriers and non-carriers, consistent 
with our previous study [22]. Based on this finding, 
PVC images were retained for subsequent analyses. 
After adjusting for age and years of education, 
ROI analysis revealed significantly higher ROI SUVRs 
between FACs compared to the NFACs with AD in 
the lateral temporal, parietal, posterior cingulate, 
medial temporal, inferior temporal, entorhinal cortex, 
amygdala and parahippocampal gyrus (P < 0.05; 
Figure 2). Voxelwise analysis revealed higher SUVR 
between FACs compared to the NFACs with AD in 
clusters corresponding to the bilateral middle 
temporal, middle temporal pole, inferior temporal, 
entorhinal cortex, parahippocampal gyrus, amygdala, 
left superior temporal, parietal, middle occipital, 
precentral, middle frontal, superior frontal and 
middle orbitofrontal lobe (P < 0.001, Figure 3, Table 2) 
after adjusting for age and years of education. 
Sex modifies the APOE ε4 effect on gray 
matter volume measured by structural MRI 
ROI-based analysis revealed significantly lower 
gray matter volume among FACs compared to the 
NFACs in the posterior cingulate, medial temporal, 
inferior temporal and amygdala after adjusting for 
age and years of education (P < 0.05; Figure 4). In 
voxelwise analysis, FACs had decreased gray matter 
volume in clusters located in the left inferior temporal, 
inferior occipital, middle temporal, middle occipital, 
amygdala, posterior cingulate; right superior 
temporal pole, superior occipital, precuneus, bilateral 
superior-medial frontal, supplementary motor area 
and superior frontal lobe compared to the NFACs 
after adjusting for age and years of education (P < 
0.001, Figure 5, Table 3). 
 
 
Figure 1. Mean SUVR images of 18F-AV-1451 PET with and without partial volume correction in individuals with AD. Partial volume corrected SUVR images (A) 
show increased contrast and spatial resolution compared with the images without PVC (B). Both with and without PVC images visually demonstrate that FACs have higher 
18F-AV-1451 SUVR. FACs: female APOE ε4 carriers, PVC: partial volume correction. 






Figure 2. The FACs have higher ROI 18F-AV-1451 PET SUVRs relative to NFACs with AD. Mean (±standard deviation) of ROI 18F-AV-1451 PET SUVR for FACs 
(red) and NFACs with AD (blue) are depicted. P value was determined by a generalized linear model with age, years of education included as covariates. FACs: female APOE ε4 
carriers, NFACs: non-FACs, SUVR: standardized uptake value ratio. 
 
 
Figure 3. 18F-AV-1451 SUVR voxelwise difference between FACs and 
NFACs with AD. T values are expressed in blue-red colors from 0 to 5 (P < 0.001, 
uncorrected, adjusted for age and years of education). FACs: female APOE ε4 
carriers, NFACs: non-FACs. 
 
Association between tau SUVR and gray 
matter volume 
We then sought to identify associations between 
tau deposition and gray matter volume. 18F-AV-1451 
SUVR was associated with gray matter volume of the 
temporal, parietal, posterior precuneus, occipital, 
entorhinal cortex, amygdala and parahippocampal 
regions (P < 0.05, Figure 6). 
Discussion 
By extending previous work on APOE ε4-sex 
interaction effects on brain tau deposition in 
cognitively normal and MCI cohorts [12, 24], our 
study revealed that sex also modifies the effect of 
APOE ε4 on brain tau deposition and atrophy in 
individuals with AD using data from the ADNI 
consortium. Recent work on clinically normal 
individuals from the Harvard Aging Brain Study 
found no sex-APOE ε4 interaction effect on regional 
tau deposition. However, within the ADNI cohort, a 
sex by APOE ε4 interaction effect on brain tau 
deposition was previously found in the early Braak 
stages (Ⅰ-Ⅲ) regions including the entorhinal cortex, 
inferior temporal, amygdala, fusiform and 
parahippocampal gyrus [12, 33]. For individuals with 
MCI, sex-stratified analysis showed that FACs had 
higher tau SUVR in the entorhinal cortex, amygdala, 
fusiform, parahippocampal gyrus, posterior 
cingulate, occipital, temporal, parietal and posterior 
precuneus (Braak stages Ⅰ-Ⅴ) compared to NFACs 
[24]. In this study, we focused on older adults with 
AD, and found that FACs had more tau deposition in 
the temporal, parietal, post cingulate, entorhinal 
cortex, amygdala, parahippocampal gyrus (Braak 
stages Ⅰ-Ⅴ) regions compared to the NFACs. Overall, 
our results add to a growing body of work 
demonstrating an APOE ε4 and sex interaction effect 
in AD whereby FACs exhibit greater brain 
region-specific tau deposition compared to NFACs 
across sub-clinical and clinical stages of AD. 
Recent metabolic and transcriptomic data add 
potential mechanistic explanations to the findings of 
this study [34-37]. For example, prior work has found 
that specific metabolic effects were limited to FACs. A 
recent study found that, among FACs, higher 
acylcarnitine C10 was associated with higher CSF 
p-tau, and higher proline levels were associated with 
reduced brain glucose uptake. These effects were not 





observed in the NFACs, suggesting that FACs 
experience greater impairment of mitochondrial 
energy production compared to NFACs with AD [36]. 
This provides an additional line of support for the 
findings drawn in this work. Moreover, in-vitro and 
transcriptomic data has suggested that sex modulates 
neuroinflammation, another risk factor for AD, with 
inflammatory dysregulation being stronger in females 
with AD [37, 38]. APOE ε4 also triggers neuro-
inflammatory cascades that cause neurovascular 
dysfunction resulting in leakage of blood derived 
toxic proteins into the brain [39]. These data suggest a 
potential model of AD pathogenesis in which the 
female sex and APOE ε4 allele contribute to 
neuroinflammatory damage to the brain and brain 
microvasculature, leading to increased tau and brain 
atrophy in FACs. 
Strikingly, although FACs had greater tau 
deposition, we observed no differences in MMSE 
score, global CDR and CDR-SOB between FACs and 
NFACs. The implication that FACs exhibit increased 
tau deposition without commensurate cognitive 
decline warrants further investigation. This may 
suggest that FACs experience greater cognitive 
resilience to the effects of tauopathy compared to 
males [24]. This is supported by a 18F-FDG PET study 
in which cognitively normal female adults had a 
younger metabolic brain age compared with males 
[40]. 
We also evaluated sex by APOE ε4 interaction 
effects on brain region-specific atrophy. FACs had a 
significant lower gray matter volume in the cingulate, 
medial temporal, inferior temporal and amygdala 
cortex than the NFACs with AD after adjusting for 
age and years of education. Previous studies have 
demonstrated that APOE ε4 allele is associated with 
significantly lower hippocampal gray matter volume 
in females with MCI and AD, but not in males [9, 25]. 
Consistent with past findings, our ROI-based and 
voxelwise analysis showed that FACs had reduced 
gray matter volume in several cortical regions 
compared with the NFACs. Moreover, we also found 
negative correlations between brain regional tau PET 
uptake and grey matter volume, which is consistent 
with existing studies [41, 42]. This suggests that tau 
pathology is a major driver of local and distant 
cortical atrophy [20, 43]. 
 
Table 2. Clusters with increased tau deposition among FACs with 
AD 
Clusters  Cluster size Atlas Coordinates Z score P value 
X Y Z 
Middle temporal/  









L 9892 -42 -54 60 6.27 < 0.001 
Parahippocampal/ 









L 1416 -43 46 21 5.00 < 0.001 
Notes: The data were extracted from voxels associated with maximally significant 
18F-AV451 PET SUVR increases in FACs compared with the NFACs with AD, after 
controlling for age and years of education. Cluster locations correspond to the brain 
maps shown in Figure 3 and correspond to P < 0.001. Atlas coordinates were 
obtained from the AAL atlas. The X, Y and Z coordinates are shown in the MNI 
space. FACs: female APOE ε4 carriers. 
 
 
Figure 4. The FACs had lower ROI gray matter volume relative to NFACs with AD. Mean (± standard deviation) of ROI gray matter volume for FACs (red) and 
NFACs (blue) with AD are depicted. P values were determined by a generalized linear model with age, years of education were included as covariates. For consistency, the 
regions displayed are those in which FACs have significantly higher ROI 18F-AV-1451 PET SUVRs from Figure 2. FACs: female APOE ε4 carriers, NFACs: non-FACs, SUVR: 
standardized uptake value ratio. 






Figure 5. Voxelwise difference of gray matter density between FACs and 
NFACs with AD. T values are expressed along the blue-red scale from -5 to 0 (P < 
0.001, adjusted for age and years of education). FACs: female APOE ε4 carriers, 
NFACs: non-FACs. 
 
Table 3. Clusters with decreased gray matter volume among 
FACs with AD 




Z score P value 
X Y Z 
Inferior temporal/ 
Occipital. 
L 653 -54 -52.5 -22.5 -4.04 < 0.001 
Superior temporal pole R 135 58.5 15 -13.5 -3.78 < 0.001 
Superior temporal L 204 -63 -3 -9 -3.94 < 0.001 
Middle temporal L 446 -69 -30 1.5 -4.10 < 0.001 
Amygdala L 104 -17.5 -4.5 -16.5 -4.35 < 0.001 
Middle occipital L 137 -45 -82.5 10.5 -4.16 < 0.001 
Superior occipital/ 
Precuneus. 
R 762 27 -84 39 -4.73 < 0.001 





L/R 3003 1.5 54 42 -5.41 < 0.001 
Notes: The data were extracted from voxels associated with maximally significant 
gray matter volume decreases in FACs compared to the NFACs with AD, after 
controlling for age and years of education. Listed locations correspond to the brain 
maps shown in Figure 5 and correspond to P < 0.001. Atlas coordinates were 
obtained from the AAL atlas. The X, Y and Z coordinates are shown in the MNI 
space. FACs: female APOE ε4 carriers, NFACs: non-FACs. 
 
 
In the current study, we pooled data from female 
APOE ε4 non-carriers, male APOE ε4 carriers and 
male APOE ε4 non-carriers into a group labeled 
NFACs. To evaluate whether similar results persist 
when using not pooled data, we also analyzed group 
comparisons for 18F-AV-1451 SUVRs between FACs 
and female APOE ε4 non-carriers, male APOE ε4 
carriers, male APOE ε4 non-carriers respectively. The 
results from both “not pooled” and “pooled” data 
were highly consistent across 6 out of the 8 originally 
significant ROIs including the lateral temporal, 
medial temporal, inferior temporal, entorhinal cortex, 
amygdala and parahippocampal gyrus. In the “non- 
pooled” data, the SUVRs of posterior cingulate and 
parietal showed a marginal P value between FACs 
and female APOE ε4 non-carriers, male APOE ε4 
carriers, male APOE ε4 non-carriers (posterior 
cingulate: P = 0.07, 0.10, 0.08 and parietal: P = 0.12, 
0.13, 0.09, respectively), but significant group 
differences were observed after “pooling” the data (P 
= 0.025 and 0.043). The findings suggest that the 
increased sample size from pooling data enhanced the 
study’s statistical power to discover FAC-associated 
effects. 
Limitations of this study must be considered 
when interpreting the results. First, our analysis was 
an observation study within the multicenter ADNI 
cohort. The high biological and physiological 
heterogeneity in AD related to age, sex and disease 
stage, and the relatively small number of AD subjects 
(15 FACs and 42 NFACs, all of whom received 
18F-AV-1451 tau PET scans and APOE ε4 genotyping) 
may limit the generalizability of results from the 
study. For example, in our cohort the age range was 
55-93 (78.98 ± 9.22 years) and CDR range was 0.5-2.0. 
Given that the effects of sex and APOE ε4 are known 
to vary significantly across disease stage and age 
groups [44, 45], our results should be interpreted 
within the age range in this cohort. It should be noted, 
however, that the frequency of FACs was 26.3%, 
which is comparable to an existing study [46]. Further, 
due to its robustness within smaller sample sizes, a 
GLM was used to assess group differences in tau 
deposition and brain atrophy at both ROI and 
voxelwise levels. We also evaluated the probability 
that the current results are affected by sample size by 
calculating the statistical power for tau SUVR to 
distinguish FACs and NFACs. The statistical power 
ranged from 0.725 to 0.999 with power > 0.8 in 10 out 
of the 12 study ROIs. The statistical power for gray 
matter volume to distinguish between the two groups 
ranged from 0.220 to 0.999, with power > 0.8 in 5 out 
of the 12 study ROIs. This suggests that tau-PET may 
be more sensitive than spatial MRI to elucidate APOE 
ε4 and sex effects in AD. 
Considering the exploratory nature of our study, 
our sample size and the correlated nature of the tau 
positive study ROIs [47, 48], we choose to minimize 
the probability of false negatives and include results 
without multiple comparisons correction in the main 
results. We recognize that this will increase our false 
positive rate and have evaluated robustness to false 
positives by applying the Benjamini-Hochberg 
method for ROI based analyses and family wise error 
(FWE) correction for voxelwise analyses. For the 
ROI-based 18F-AV-1451 analysis, all regions remained 
significant at false discovery rates (FDR) < 0.1 [24]. For 
the ROI-based gray matter analysis, three regions i.e. 
the amygdala, inferior temporal and posterior 





cingulate remained significant at FDR < 0.1. All 
regions remained significant at FDR < 0.2. For the 
voxelwise 18F-AV-1451 analysis, clusters in the right 
inferior temporal, left amygdala, inferior parietal, 
superior parietal, bilateral entorhinal cortex and 
parahippocampal gyrus regions remained significant 
after FWE correction. For the voxelwise gray matter 
analyses, no clusters survived FWE correction. 
Further, we acknowledge that the current work 
is based on the ADNI cohort and may not generalize 
to other AD patient populations. Future analyses 
should be conducted in multi institutional cohorts 
beyond ADNI with larger sample sizes to validate this 
preliminary work. 
Conclusion 
In summary, sex modifies the effects of the 
APOE ε4 allele on brain region-specific tau deposition 
and gray matter volume in older adults with AD. 
Specifically, FACs exhibited elevated brain 
region-specific tau PET SUVR and deceased gray 
matter volume. Results from this study advance our 
understanding of the effect of sex and APOE ε4 in 
promoting tau pathology in AD. Importantly, this 
work highlights the importance of considering sex 
and APOE ε4 in biomarker development, clinical trial 
endpoint evaluation, and mechanistic studies in AD 
using quantitative 18F-AV-1451 PET. 
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